Diagnostic Utility of Cytomegalovirus Nucleic Acid Testing during Antigenemia-Guided Cytomegalovirus Monitoring after Hematopoietic Stem Cell Transplantation or Liver Transplantation
Open Access
- 1 January 2019
- journal article
- research article
- Published by Tohoku University Medical Press in The Tohoku Journal of Experimental Medicine
- Vol. 247 (3) , 179-187
Abstract
Cytomegalovirus (CMV) is an opportunistic pathogen, and careful monitoring of CMV is important for immunocompromised patients. Antigenemia-based CMV monitoring is a standard test used for managing CMV infection in transplant recipients; however, in Japan, there are no reports of CMV monitoring using the standardized test. The utility of a standardized CMV nucleic acid test (NAT) was evaluated during antigenemia-based CMV monitoring after hematopoietic stem cell transplantation (HSCT) or liver transplantation. Blood collection for CMV monitoring was performed under the physician’s instructions depending on the condition of the patient, and CMV NAT and antigenemia was evaluated. For HSCT recipients, blood collection only for NAT was additionally performed during the pre-engraftment phase. The results of the NAT were blinded to those evaluating the results. A total of 34 patients were enrolled (11 HSCT recipients and 23 liver transplant recipients). NAT detected the first CMV episode no later than antigenemia in 2 (18.2%) HSCT recipients and 3 (13.0%) liver transplant recipients, earlier than antigenemia in 3 (27.3%) HSCT recipients and 7 (30.4%) liver transplant recipients, and later than antigenemia in 1 (9.1%) HSCT recipient and 1 (4.3%) liver transplant recipient. In 5 HSCT recipients, NAT was positive during the pre-engraftment phase. Among the 468 blood samples which were evaluated by both NAT and antigenemia, 124 (26.7%) were positive in NAT and 51 (10.9%) were positive in antigenemia. The standardized CMV NAT is useful for accurately diagnosing CMV infection and determining appropriate therapeutic interventions for HSCT recipients and liver transplant recipients.Keywords
This publication has 15 references indexed in Scilit:
- Diagnostic test accuracy of antigenaemia assay for PCR-proven cytomegalovirus infection—systematic review and meta-analysisClinical Microbiology and Infection, 2017
- Evaluation of COBAS AmpliPrep/COBAS TaqMan CMV Test for use in hematopoietic stem cell transplant recipientsExpert Review of Molecular Diagnostics, 2017
- Allogeneic hematopoietic stem cell transplant recipients and parasitic diseases: A review of the literature of clinical cases and perspectives to screen and follow‐up active and latent chronic infectionsTransplant Infectious Disease, 2017
- Development and evaluation of a quantitative assay detecting cytomegalovirus transcripts for preemptive therapy in allogeneic hematopoietic stem cell transplant recipientsJournal of Medical Virology, 2017
- An overview of infectious complications after allogeneic hematopoietic stem cell transplantationJournal of Infection and Chemotherapy, 2016
- Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016Annals of Hematology, 2016
- Cytomegalovirus diseases after hematopoietic stem cell transplantation: A mini-reviewCancer Letters, 2014
- Updated International Consensus Guidelines on the Management of Cytomegalovirus in Solid-Organ TransplantationTransplantation, 2013
- Algorithm based on CMV kinetics DNA viral load for preemptive therapy initiation after hematopoietic cell transplantationJournal of Medical Virology, 2011
- Interlaboratory Comparison of Cytomegalovirus Viral Load AssaysAmerican Journal of Transplantation, 2009